Live tape
Top 8, mentions 7d27,369NVDA16,648 mentions▲ +0.03MSFT1,929 mentions▼ -0.03GOOGL1,914 mentions▲ +0.04AMD1,656 mentions▲ +0.09AAPL1,518 mentions▲ +0.05SPCX1,452 mentions▲ +0.07NBIS1,214 mentions▲ +0.07SPY1,038 mentions▲ +0.05

Equity · Healthcare

NBIX

NASDAQ

Neurocrine Biosciences (NBIX)

157 USD +1.21% vs prior close Sep 10, 2026
Neurocrine Biosciences, Inc. price graph
16 sessions
160 152 19 Aug 10 Sep

The line runs 155.56 USD on 19 August through 157 USD on 10 September, on a scale from 152 to 160. Days the market did not trade hold the previous close, flat.

Market cap
15.9B USD
P/E (TTM)
23.3
Revenue, year to Dec 2025
2.9B USD
EPS, diluted, year to Dec 2025
4.67 USD
52-week range
123 USD – 181 USD
Avg volume
113.6K

as of Sep 10, 2026

Have Neurocrine Biosciences (NBIX) insiders bought or sold shares recently?

In the 90 days to 17 Nov 2026, Neurocrine Biosciences insiders reported 6 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 13 Feb 2026, show no open-market purchase.

Form 4, 90 days to 17 Nov 2026, newest reported trade 3 Nov 2026

0buys
6sells
$3.16Mnet sold
27other filings
Have Neurocrine Biosciences (NBIX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
03 Nov 2026MORROW GEORGE JDirectorSell7,2001.2M USD
02 Nov 2026MORROW GEORGE JDirectorSell7,5001.1M USD
30 Oct 2026MORROW GEORGE JDirectorSell30045K USD
14 Sep 2026ABERNETHY MATTChief Financial OfficerSell2,311363K USD
14 Sep 2026Boyer David W.Chief Corp. Affairs OfficerSell826130K USD
09 Sep 2026BENEVICH ERICChief Commercial OfficerSell2,154333K USD
Sold6 open-market sales20,291$3.16M
27 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Neurocrine Biosciences (NBIX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
03 Nov 2026MORROW GEORGE JDirectorOption exercise7,200386K USD
02 Nov 2026MORROW GEORGE JDirectorOption exercise7,500402K USD
01 Nov 2026Gano KyleChief Executive OfficerOption exercise614
01 Nov 2026Gano KyleChief Executive OfficerTax withheld33249K USD
30 Oct 2026MORROW GEORGE JDirectorOption exercise30016K USD
11 Sep 2026ABERNETHY MATTChief Financial OfficerAward5,020
11 Sep 2026ABERNETHY MATTChief Financial OfficerTax withheld2,709423K USD
11 Sep 2026BENEVICH ERICChief Commercial OfficerAward6,275
11 Sep 2026BENEVICH ERICChief Commercial OfficerTax withheld3,386529K USD
11 Sep 2026Boyer David W.Chief Corp. Affairs OfficerAward3,587
11 Sep 2026Boyer David W.Chief Corp. Affairs OfficerTax withheld1,936302K USD
11 Sep 2026Cooke JulieChief Human Resources OfficerAward3,587

Showing the 12 most recent of 27 compensation filings in this window. The figures above count all of them.

Which funds hold Neurocrine Biosciences (NBIX)?

12 of the 45 institutional funds we track reported a Neurocrine Biosciences position for the quarter ended 30 Sep 2026 — a combined 937.7M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Neurocrine Biosciences (NBIX)?
FundPositionSharesValueShares q/q
AQR Capital ManagementHeld (±25%)3,062,385422.5M USD−19.8%
Renaissance TechnologiesHeld (±25%)2,300,697326.3M USD−1.5%
Man GroupHeld (±25%)474,28767.3M USD−21.1%
Millennium ManagementAdded368,83952.3M USD+3,083.8%
Bridgewater AssociatesHeld (±25%)206,38629.3M USD+0.3%
Balyasny Asset ManagementNew position139,93719.8M USD
Two Sigma InvestmentsTrimmed76,78010.9M USD−96.3%
Citadel AdvisorsAdded36,3825.2M USD+206.7%
Fisher Asset ManagementTrimmed16,4672.3M USD−87.8%
D. E. Shaw & Co.Held (±25%)6,724954K USD+20.1%

Showing the 10 largest of 12 reported positions. The figures above count all of them.

Have members of Congress traded Neurocrine Biosciences (NBIX)?

The most recent congressional trade disclosed in Neurocrine Biosciences is a sale by Lisa C. McClain (house, MI), dated 17 Jun 2025.

STOCK Act disclosures

Have members of Congress traded Neurocrine Biosciences (NBIX)?
TradedMemberTypeAmountFiled after
17 Jun 2025Lisa C. McClainhouse · Republican–MISale1K USD–15K USD57 days
11 Jun 2025Lisa C. McClainhouse · Republican–MIPurchase1K USD–15K USD63 days

What has been filed or recorded for Neurocrine Biosciences (NBIX)?

The filings we hold for Neurocrine Biosciences, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 20 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Neurocrine Biosciences (NBIX)?
And
20 Oct 2026Fails to deliverShares failed to deliver6,639 shares909K USD notional · 0.007% of shares out
09 Oct 2026Fails to deliverShares failed to deliver891 shares126K USD notional · 0.001% of shares out
05 Oct 2026Fails to deliverShares failed to deliver1 shares143 USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 1.96 USD
30 Sep 2026FinancialsTotal assets5.6B USDat period end
30 Sep 2026FinancialsTotal equity3.9B USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 1.39 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 1.91 USD
31 Dec 2025Annual reportFY 2025 reportedEPS 4.67 USD
31 Dec 2025FinancialsRevenue2.9B USDfiscal year
31 Dec 2025FinancialsNet income478.6M USDfiscal year
31 Dec 2025FinancialsDiluted EPS4.67 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 2.04 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 1.06 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 0.08 USD
31 Dec 2024Annual reportFY 2024 reportedEPS 3.29 USD

What do people ask about Neurocrine Biosciences (NBIX)?

From live data
What did Neurocrine Biosciences shares close at?157.00

Neurocrine Biosciences closed at 157.00 USD on 10 Sep 2026, up 1.21% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Neurocrine Biosciences’ market cap?15.9B

Neurocrine Biosciences is worth 15.9B USD by market value as of 10 Sep 2026, which is the share price times the shares on issue from its SEC filings.

What is Neurocrine Biosciences’ P/E ratio?23.3

Neurocrine Biosciences has a price-to-earnings ratio of 23.3, as of 10 Sep 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

What is Neurocrine Biosciences’ revenue?2.9B

Neurocrine Biosciences reported revenue of 2.9B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Neurocrine Biosciences insiders bought or sold shares recently?6 sales

In the 90 days to 17 Nov 2026, Neurocrine Biosciences insiders reported 6 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 13 Feb 2026, show no open-market purchase. A further 27 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Neurocrine Biosciences?12 of 45

12 of the 45 funds we track reported a Neurocrine Biosciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Renaissance Technologies and Man Group. See Funds

Have members of Congress traded Neurocrine Biosciences?2 trades

Yes. 2 trades in Neurocrine Biosciences appear in the congressional disclosures we hold; the latest is a sale by Lisa C. McClain (House, MI) dated 17 Jun 2025, filed 13 Aug 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Neurocrine Biosciences last report earnings?1.96

Neurocrine Biosciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 1.96 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. Wikimedia CommonsPortraits via Wikimedia Commons. Lisa C. McClain: Office of Congresswoman Lisa McClain, Public domain.
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SECSEC fails-to-deliver (CNS) data
  8. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  9. SEC EDGARreported earnings figures and scheduled report dates
  10. SEC EDGARValuation computed from SEC EDGAR filings